China found that it can inhibit the growth and migration of breast cancer

The reporter learned from the China University of Science and Technology that Liu Suling, a professor at the School of Life Sciences, has made new breakthroughs in cancer stem cell research and discovered that a small RNA molecule called microRNA100 (miR-100) can inhibit the regeneration and proliferation of breast cancer stem cells. Thus suppressing the growth and migration of breast cancer. The results were published online today in the internationally renowned academic journal Cancer Research.

Scientists at the University of Science and Technology have found that the expression level of miR-100 is related to the differentiation status of cells. In breast cancer stem cells, the expression level of miR-100 is very low, which promotes the differentiation of breast cancer stem cells. The use of tetracycline-inducible lentivirus to increase the expression of miR-100 in breast tumor cells can reduce the generation of breast cancer stem cells.

Further mechanistic studies have shown that miR-100 down-regulates the expression of several regulatory genes of breast cancer stem cells, including SMARCA5, SMARCD1, and BMPR2, and inhibits cancer cell proliferation both in tumor cell experiments and in mouse experiments. They also implanted tumor cells into the mouse mammary fat pad and injected into the mouse heart, and immediately induced high expression of miR-100 in mice, which was found to prevent tumor growth and metastasis. In addition, they transported miR-100 into cancer stem cells via nanocarriers, thereby inhibiting tumor growth. Clinically, they observed a significant positive correlation between miR-100 levels in breast cancer samples and patient survival. Reviewers of the "Cancer Research" magazine commented that this study demonstrated for the first time the effects of miR-100 on breast tumors and provided new ideas for the close relationship between microRNAs and cancer stem cells and for breast cancer research and treatment. direction.

Liu Suling said that this study demonstrates that miR-100 plays a crucial role in regulating the self-renewal and differentiation of breast cancer stem cells, which provides a new target for the treatment of breast cancer stem cells.